| Literature DB >> 18341794 |
Dyann M Matson Koffman1, Andrew Lanza, Kathryn Phillips Campbell.
Abstract
INTRODUCTION: In 2005, representatives from the Centers for Disease Control and Prevention partnered with the National Business Group on Health and the Agency for Healthcare Research and Quality to form a work group for developing A Purchaser's Guide to Clinical Preventive Services: Moving Science into Coverage. This guide, designed as a tool for employers, describes recommended clinical preventive services for 46 conditions. The guide includes the scientific evidence and benefits language that employers need to include comprehensive clinical preventive services in their medical benefit plans.Entities:
Mesh:
Year: 2008 PMID: 18341794 PMCID: PMC2396996
Source DB: PubMed Journal: Prev Chronic Dis ISSN: 1545-1151 Impact factor: 2.830
A Purchaser's Guide to Clinical Preventive Services: Description of Chapters
| Chapter | Title | Description |
|---|---|---|
| 1 | The Role of Clinical Preventive Services in Disease Prevention and Early Detection | Information for employers on improving the health of beneficiaries and reducing health care costs by implementing a comprehensive and structured benefit for clinical preventive services within a medical benefit plan. |
| 2 | Summary Plan Description (SPD) Language Statements for Recommended Clinical Preventive Services Benefits | Forty-six condition-specific SPD language statements designed to assist benefits staff as they design, discuss, negotiate, and set benefit structures and coverage guidelines with a health plan, union, or consumer group. |
| 3 | Evidence Statements for Recommended Clinical Preventive Service Benefits | Scientific evidence behind each of the 72 recommendations for benefits (i.e., screening, testing, counseling, immunization, preventive medication, and preventive treatment). |
| 4 | The Prioritization and Strategic Implementation of Clinical Preventive Service Benefits | Practical advice and employer scenarios regarding the strategic implementation of benefits. |
| 5 | Clinical Preventive Services: Recommendations and Statements of the U.S. Preventive Services Task Force (USPSTF) | Information on clinical preventive services that were reviewed by the USPSTF but not included in the |
| 6 | Leveraging Benefits: Opportunities to Promote the Delivery and Use of Preventive Services | Actions that employers can take to strengthen prevention efforts by supporting or implementing public health interventions in the workplace and in communities. |
| 7 | Resources and Tools | Additional information for employers on clinical preventive services, including "at a glance" guides to disease prevention throughout the life span and other helpful tools. |
PDF copies of the Purchaser's Guide are available on the Web sites of the National Business Group on Health (www.businessgrouphealth.org/prevention/purchasers) and the Centers for Disease Control and Prevention (www.cdc.gov/business).
High-Value Preventive Servicesa(5), by Rank Order
| Service | CPB —Maximum Score = 5 | CE —Maximum Score = 5 | Combined Score CPB and CE —Maximum Score = 10 |
|---|---|---|---|
| Aspirin chemoprophylaxis | 5 | 5 | 10 |
| Childhood immunization series | 5 | 5 | 10 |
| Tobacco use, screening and brief intervention | 5 | 5 | 10 |
| Problem drinking, screening and brief counseling | 4 | 4 | 8 |
| Colorectal cancer screening | 4 | 4 | 8 |
| Hypertension screening | 5 | 3 | 8 |
| Influenza immunization | 4 | 4 | 8 |
| Pneumococcal immunization | 3 | 5 | 8 |
| Vision screening (adults) | 3 | 5 | 8 |
| Cervical cancer screening | 4 | 3 | 7 |
| Cholesterol screening | 5 | 2 | 7 |
| Breast cancer screening | 4 | 2 | 6 |
| Calcium chemoprophylaxis | 3 | 3 | 6 |
| Chlamydia screening | 2 | 4 | 6 |
| Vision screening (children) | 2 | 4 | 6 |
| Folic acid chemoprophylaxis | 2 | 3 | 5 |
| Obesity screening | 3 | 2 | 5 |
| Depression screening | 3 | 1 | 4 |
| Hearing screening | 2 | 2 | 4 |
| Injury prevention, counseling | 1 | 3 | 4 |
CPB indicates clinically preventable burden; CE, cost-effectiveness.
Evaluated in terms of the clinically preventable burden of disease and cost-effectiveness.